Literature DB >> 20952027

Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen.

Todd M Morgan1, Christopher J Welty, Funda Vakar-Lopez, Daniel W Lin, Jonathan L Wright.   

Abstract

PURPOSE: The clinical significance of ductal prostatic carcinoma is not well-defined. In a population based cancer registry we identified a large group of patients with ductal carcinoma to characterize the impact of the ductal subtype on presentation and survival in men with prostate cancer.
MATERIALS AND METHODS: We used a national cancer registry to identify incident cases of ductal and acinar adenocarcinoma from 1996 to 2006. We analyzed clinicopathological variables and performed Cox multivariate survival analysis. Prostate specific antigen values were available for 2004 to 2006 and used to assess differences in Gleason grade and serum prostate specific antigen between ductal and acinar cancer cases at diagnosis.
RESULTS: We identified 442,881 acinar and 371 ductal cases. Ductal cases were more likely to present with distant disease (12% vs 4%, p <0.001) and be poorly differentiated (50% vs 32%, p <0.001). Ductal histology was associated with a 30% decrease in geometric mean prostate specific antigen (adjusted coefficient 0.7, 95% CI 0.6-0.8) and more than 2-fold increased odds of prostate specific antigen less than 4.0 ng/ml (OR 2.4, 95% CI 1.4-4.0) independent of other clinicopathological variables. In men with nondistant disease at diagnosis ductal histology was associated with 2.2-fold (CI 1.4-3.5) increased disease specific mortality.
CONCLUSIONS: In what is to our knowledge the largest series of this histological subtype ductal cancer cases were more likely to present with advanced stage cancer and lower prostate specific antigen, suggesting that timely disease detection is a significant challenge. Also, men with locoregional disease were more likely to die of the disease.
Copyright © 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20952027      PMCID: PMC3111052          DOI: 10.1016/j.juro.2010.08.017

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  22 in total

1.  Prostatic adenocarcinoma of ductal origin.

Authors:  L F Greene; G M Farrow; J M Ravits; F M Tomera
Journal:  J Urol       Date:  1979-03       Impact factor: 7.450

2.  Endometrial carcinoma of proxtatic utricle (uterus masculinus).

Authors:  M M Melicow; M R Pachter
Journal:  Cancer       Date:  1967-10       Impact factor: 6.860

3.  Prostatic adenocarcinoma of ductal origin.

Authors:  V E Dube; G M Farrow; L F Greene
Journal:  Cancer       Date:  1973-08       Impact factor: 6.860

4.  Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression.

Authors:  D A Brinker; S R Potter; J I Epstein
Journal:  Am J Surg Pathol       Date:  1999-12       Impact factor: 6.394

5.  Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases.

Authors:  B Têtu; J Y Ro; A G Ayala; D E Johnson; C J Logothetis; N G Ordonez
Journal:  Cancer       Date:  1987-05-15       Impact factor: 6.860

6.  Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features.

Authors:  Shi-Ming Tu; Adriana Reyes; April Maa; Deb Bhowmick; Louis L Pisters; Curtis A Pettaway; Sue-Hwa Lin; Patricia Troncoso; Christopher J Logothetis
Journal:  Cancer       Date:  2002-05-15       Impact factor: 6.860

7.  Ductal adenocarcinoma of the prostate diagnosed on transurethral biopsy or resection is not always indicative of aggressive disease: implications for clinical management.

Authors:  Hakan Aydin; Jun Zhang; Hemamali Samaratunga; Nelly Tan; Cristina Magi-Galluzzi; Eric Klein; J Stephen Jones; Ming Zhou
Journal:  BJU Int       Date:  2009-08-25       Impact factor: 5.588

8.  Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases.

Authors:  J I Epstein; J M Woodruff
Journal:  Cancer       Date:  1986-01-01       Impact factor: 6.860

9.  Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings.

Authors:  D G Bostwick; R W Kindrachuk; R V Rouse
Journal:  Am J Surg Pathol       Date:  1985-08       Impact factor: 6.394

10.  Papillary carcinoma of the prostate, location, morphology, and immunohistochemistry: the histogenesis and entity of so-called endometrioid carcinoma.

Authors:  N Wernert; H Lüchtrath; H Seeliger; M Schäfer; R Goebbels; G Dhom
Journal:  Prostate       Date:  1987       Impact factor: 4.104

View more
  34 in total

1.  Prostatic ductal adenocarcinoma: an aggressive tumour variant unrecognized on T2 weighted magnetic resonance imaging (MRI).

Authors:  Nicola Schieda; Niamh Coffey; Previn Gulavita; Omran Al-Dandan; Wael Shabana; Trevor A Flood
Journal:  Eur Radiol       Date:  2014-04-01       Impact factor: 5.315

2.  Ductal and Acinar Adenocarcinoma of Prostate: Morphological and Immunohistochemical Characterization.

Authors:  Faraz A Baig; Amna Hamid; Talat Mirza; Serajuddaula Syed
Journal:  Oman Med J       Date:  2015-05

3.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Authors:  Carlos L Morais; Mehsati Herawi; Antoun Toubaji; Roula Albadine; Jessica Hicks; George J Netto; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

Review 4.  The update of prostatic ductal adenocarcinoma.

Authors:  Tantan Liu; Yingmei Wang; Ru Zhou; Haiyang Li; Hong Cheng; Jing Zhang
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

5.  Regional trends in average years of potential life lost (AYPLL) secondary to prostate cancer deaths among Caucasians and African Americans treated by surgery or radiation.

Authors:  Mohamed H Kamel; Milan Bimali; Mahmoud I Khalil; Ehab Eltahawy; LJoseph Su; Nabil K Bissada; Rodney Davis
Journal:  Int Urol Nephrol       Date:  2019-03-06       Impact factor: 2.370

6.  Advanced prostatic ductal carcinoma in a patient with a long survival time following a total pelvis exenteration: A case report.

Authors:  Changwei Ji; Ming Zhou; Weidong Gan; Jinyu Zheng; Xiang Yan; Hongqian Guo
Journal:  Oncol Lett       Date:  2016-01-08       Impact factor: 2.967

7.  Pathologic stage of prostatic ductal adenocarcinoma at radical prostatectomy: effect of percentage of the ductal component and associated grade of acinar adenocarcinoma.

Authors:  Ali Amin; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2011-04       Impact factor: 6.394

8.  Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens.

Authors:  Amanda H Seipel; Fredrik Wiklund; N Peter Wiklund; Lars Egevad
Journal:  Virchows Arch       Date:  2013-02-27       Impact factor: 4.064

9.  Ductal adenocarcinoma of the prostate: a Hong Kong case series.

Authors:  Raymond Wai Man Kan; Chi Fai Kan; Joseph Hon Ming Wong; Kenneth Kam Fung Fu; Chi Fai Ng; Steve Wai Hee Chan
Journal:  Int Urol Nephrol       Date:  2014-07-31       Impact factor: 2.370

Review 10.  Biopsy-proven brain metastases from prostate cancer: a series of four cases with review of the literature.

Authors:  C E Gzell; J G Kench; M R Stockler; G Hruby
Journal:  Int Urol Nephrol       Date:  2013-05-11       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.